Related references
Note: Only part of the references are listed.Blood substitutes: why haven't we been more successful?
Abdu I. Alayash
TRENDS IN BIOTECHNOLOGY (2014)
Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety
Paula H. B. Bolton-Maggs et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories
C. Milkins et al.
TRANSFUSION MEDICINE (2013)
Transfusion safety in 2012: main messages from the SHOT Annual Report for 2012
P. H. B. Bolton-Maggs
TRANSFUSION MEDICINE (2013)
Where are we at with point- of- care testing in haematology?
Carol Briggs et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Main Properties of the THERAFLEX MB-Plasma System for Pathogen Reduction
Jerard Seghatchian et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2011)
Setbacks in Blood Substitutes Research and Development: A Biochemical Perspective
Abdu I. Alayash
CLINICS IN LABORATORY MEDICINE (2010)
Hemoglobin-based Oxygen Carriers Current Status and Future Directions
Toby A. Silverman et al.
ANESTHESIOLOGY (2009)
Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats
Vic Ciaravino et al.
TRANSFUSION (2009)
Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG (R)
A. Neisser-Svae et al.
VOX SANGUINIS (2009)
Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death - A meta-analysis
Charles Natanson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Toxicity Testing of a Novel Riboflavin-Based Technology for Pathogen Reduction and White Blood Cell Inactivation
Heather L. Reddy et al.
TRANSFUSION MEDICINE REVIEWS (2008)
A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas®) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment
Andrea Heger et al.
TRANSFUSION AND APHERESIS SCIENCE (2006)
Stability of solvent/detergent-treated plasma and single-donor fresh-frozen plasma during 48h after thawing
A Heger et al.
TRANSFUSION AND APHERESIS SCIENCE (2005)
Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light
LL Lin et al.
TRANSFUSION (2005)
Riboflavin and UV-light based pathogen reduction: Extent and consequence of DNA damage at the molecular level
V Kumar et al.
PHOTOCHEMISTRY AND PHOTOBIOLOGY (2004)
To filter blood or universal leukoreduction: what is the answer?
MJ Shapiro
CRITICAL CARE (2004)
Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria
L Lin et al.
TRANSFUSION (2004)
Preclinical safety profile of plasma prepared using the INTERCEPT Blood System
V Ciaravino et al.
VOX SANGUINIS (2003)
Viral safety of solvent/detergent-treated plasma
BG Solheim et al.
TRANSFUSION (2000)
Share Paper
